HRP20100127T1 - Višečestični oblici - Google Patents
Višečestični oblici Download PDFInfo
- Publication number
- HRP20100127T1 HRP20100127T1 HR20100127T HRP20100127T HRP20100127T1 HR P20100127 T1 HRP20100127 T1 HR P20100127T1 HR 20100127 T HR20100127 T HR 20100127T HR P20100127 T HRP20100127 T HR P20100127T HR P20100127 T1 HRP20100127 T1 HR P20100127T1
- Authority
- HR
- Croatia
- Prior art keywords
- multiparticle
- oxycodone
- forms according
- pharmaceutical composition
- plasticizer
- Prior art date
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract 16
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims abstract 14
- 229960002085 oxycodone Drugs 0.000 claims abstract 13
- 239000003607 modifier Substances 0.000 claims abstract 11
- 230000035699 permeability Effects 0.000 claims abstract 11
- 229920001577 copolymer Polymers 0.000 claims abstract 10
- 239000000314 lubricant Substances 0.000 claims abstract 9
- 239000004014 plasticizer Substances 0.000 claims abstract 9
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract 3
- 238000013270 controlled release Methods 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 7
- 239000004615 ingredient Substances 0.000 claims 6
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical group CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- 229940049654 glyceryl behenate Drugs 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 229920003156 Eudragit® RL PO Polymers 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol group Chemical group C(CCCCCCCCCCCCCCC)O BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims 1
- 229920003160 Eudragit® RS PO Polymers 0.000 claims 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 1
- 230000036592 analgesia Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 229940082500 cetostearyl alcohol Drugs 0.000 claims 1
- 229960000541 cetyl alcohol Drugs 0.000 claims 1
- 238000001125 extrusion Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 229960003617 oxycodone hydrochloride Drugs 0.000 claims 1
- 229940105606 oxycontin Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 229960002920 sorbitol Drugs 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 229940012831 stearyl alcohol Drugs 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 229960004793 sucrose Drugs 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims 1
- 239000001069 triethyl citrate Substances 0.000 claims 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 1
- 235000013769 triethyl citrate Nutrition 0.000 claims 1
- DZGUJOWBVDZNNF-UHFFFAOYSA-N azanium;2-methylprop-2-enoate Chemical compound [NH4+].CC(=C)C([O-])=O DZGUJOWBVDZNNF-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
Ekstrudirani iz otopine, višečestični oblici sa kontroliranim oslobađanjem, naznačeni time što sadrže (a) oksikodon, (b) amonijev metakrilat kopolimer netopljiv u vodi, (c) plastifikator, (d) lubrikant i (e) modifikator vodopropusnosti, pri čemu je navedeni modifikator vodopropusnosti vodopropusan amonijev metakrilat kopolimer ili hidroksipropil metilceluloza. Patent sadrži još 26 patentnih zahtjeva.
Claims (27)
1. Ekstrudirani iz otopine, višečestični oblici sa kontroliranim oslobađanjem, naznačeni time što sadrže (a) oksikodon, (b) amonijev metakrilat kopolimer netopljiv u vodi, (c) plastifikator, (d) lubrikant i (e) modifikator vodopropusnosti, pri čemu je navedeni modifikator vodopropusnosti vodopropusan amonijev metakrilat kopolimer ili hidroksipropil metilceluloza.
2. Višečestični oblici prema patentnom zahtjevu 1, naznačeni time što je oksikodon prisutan kao farmaceutski prihvatljiva sol.
3. Višečestični oblici prema patentnom zahtjevu 2, naznačeni time što je oksikodon prisutan kao oksikodon hidroklorid.
4. Višečestični oblici prema bilo kojem od patentnih zahtjeva 1 do 3, naznačeni time što je plastifikator izabran od cetil alkohola, stearil alkohola, cetostearil alkohola, sorbitola, saharoze, visoke molekularne težine - polietilen glikola, dibutil sebacata, tributil citrata, trietil citrata, propilen glikola i polietilen glikola niske molekularne težine.
5. Višečestični oblici prema patentnom zahtjevu 4, naznačeni time što je plastifikator stearil alkohol.
6. Višečestični oblici prema patentnom zahtjevu 4, naznačeni time što je plastifikator polietilen glikol visoke molekularne težine.
7. Višečestični oblici prema bilo kojem od patentnih zahtjeva 1 do 6, naznačeni time što je lubrikant izabran od gliceril behenata, talka i silikon dioksida.
8. Višečestični oblici prema patentnom zahtjevu 7, naznačeni time što je lubrikant gliceril behenat.
9. Višečestični oblici prema bilo kojem od patentnih zahtjeva 1 do 6, naznačeni time što je lubrikant stearinska kiselina ili stearat sol.
10. Višečestični oblici prema bilo kojem od patentnih zahtjeva 1 do 9, naznačeni time što je modifikator vodopropusnosti vodopropusni amonijev metakrilat kopolimer.
11. Višečestični oblici prema bilo kojem od patentnih zahtjeva 1 do 10, naznačeni time što je modifikator vodopropusnosti - Eudragit RL PO.
12. Višečestični oblici prema bilo kojem od patentnih zahtjeva 1 do 11, naznačeni time što su postotne količine sastojaka (a) do (e) kao što su navedene u slijedećoj tabeli, na temelju ukupne težine pet sastojaka:
oksikodon kao hidroklorid 3 do 50
netopljivi amonijev metakrilat kopolimer 25 do 85
plastifikator 1 do 30
lubrikant 1 do 25
modifikator vodopropusnosti 1 do 40.
13. Višečestični oblici prema patentnom zahtjevu 12, naznačeni time što su postotne količine sastojaka (a) do (e) kao što su navedene u slijedećoj tabeli, na temelju ukupne težine pet sastojaka:
oksikodon kao hidroklorid 5 do 40
netopljjivi amonijev metakrilat kopolimer 35 do 75
plastifikator 3 do 25
lubrikant 2 do 25
modifikator vodopropusnosti 1 do 30.
14. Višečestični oblici prema patentnom zahtjevu 12, naznačeni time što su procentne količine sastojaka (a) do (e) kao što su navedene u slijedećoj tabeli, na osnovu ukupne težine pet sastojaka:
oksikodon kao hidroklorid 7.5 do 35
netopljiv amonijev metakrilat kopolimer 50 do 65
plastifikator 5 do 15
lubrikant 2 do 25
modifikator vodopropusnosti 1 do 20.
15. Višečestični oblici prema patentnom zahtjevu 1, naznačeni time što sadrže oksikodon, Eudragit RS PO, stearil alkohol, gliceril behenat i Eudragit RL PO.
16. Farmaceutska kompozicija u obliku jedinične doze, naznačena time što sadrži višečestične oblike prema bilo kojem od prethodnih patentnih zahtjeva.
17. Farmaceutska kompozicija prema patentnom zahtjevu 16, naznačena time što jedinična doza osigurava dozu oksikodona koja je dovoljna da osigura analgeziju humanom pacijentu.
18. Farmaceutska kompozicija prema patentnom zahtjevu 17, naznačena time što je bioekvivalentna OxyContin® tabletama.
19. Farmaceutska kompozicija prema patentnom zahtjevu 17 ili 18, naznačena time što je dovoljna doza oksikodona 5 do 400 mg.
20. Farmaceutska kompozicija prema patentnom zahtjevu 19, naznačena time što je jedinična doza oksikodona 5 mg, 10 mg, 20 mg, 40 mg, 80 mg ili 160 mg.
21. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 16 do 20, naznačena time što je u obliku kapsule sa punjenjem od navedenih višečestičnih oblika.
22. Farmaceutska kompozicija prema patentnom zahtjevu 21, naznačena time što su višečestični oblici punjeni u tvrde želatinozne kapsule, pri čemu svaka od tih kapsula sadrži jediničnu dozu.
23. Farmaceutska kompozicija prema patentnom zahtjevu 22, naznačena time što je težina punjenja u kapsuli u opsegu od 120 do 500 mg.
24. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 16 do 23, naznačena time što je namjenjena za primjenu u intervalima od 12 sati.
25. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 16, 17 i 19 do 23, naznačena time što je namjenjena za primjenu u intervalima od 24 sata.
26. Postupak za pripremu višečestičnih oblika prema patentnom zahtjevu 1 naznačen time što sadrži pripremu mješavine koja sadrži (a) oksikodon, (b) amonijev metakrilat kopolimer koji je netopljiv u vodi, (c) plastifikator, (d) lubrikant i (e) modifikator vodopropusnosti, pri čemu je navedeni modifikator vodopropusnosti vodopropusan amonijev metakrilat kopolimer ili hidroksipropil metilceluloza; i ekstruziju mješavine.
27. Farmaceutska kompozicija naznačena time što sadrži višečestične oblike prema bilo kojem od patentnih zahtjeva 1 do 15 i višečestične oblike antagonista oksikodona.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0315137A GB0315137D0 (en) | 2003-06-27 | 2003-06-27 | Multiparticulates |
| GB0403102A GB0403102D0 (en) | 2004-02-12 | 2004-02-12 | Multiparticulates |
| GB0413454A GB0413454D0 (en) | 2004-06-16 | 2004-06-16 | Multiparticulates |
| PCT/GB2004/002705 WO2005000310A1 (en) | 2003-06-27 | 2004-06-23 | Multiparticulates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100127T1 true HRP20100127T1 (hr) | 2010-04-30 |
Family
ID=33556051
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100127T HRP20100127T1 (hr) | 2003-06-27 | 2010-03-08 | Višečestični oblici |
| HRP20140635TT HRP20140635T1 (hr) | 2003-06-27 | 2014-07-04 | Multiäśestice |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140635TT HRP20140635T1 (hr) | 2003-06-27 | 2014-07-04 | Multiäśestice |
Country Status (25)
| Country | Link |
|---|---|
| EP (2) | EP1644002B1 (hr) |
| JP (2) | JP5348841B2 (hr) |
| KR (1) | KR101116518B1 (hr) |
| AR (1) | AR044935A1 (hr) |
| AT (1) | ATE453394T1 (hr) |
| AU (1) | AU2004251481B2 (hr) |
| BR (1) | BRPI0411901B1 (hr) |
| CA (1) | CA2530385C (hr) |
| CY (2) | CY1109917T1 (hr) |
| DE (1) | DE602004024888D1 (hr) |
| DK (2) | DK1889621T3 (hr) |
| EA (1) | EA013424B1 (hr) |
| ES (2) | ES2490598T3 (hr) |
| HR (2) | HRP20100127T1 (hr) |
| IL (1) | IL172730A (hr) |
| MX (1) | MXPA05013799A (hr) |
| MY (1) | MY176831A (hr) |
| NO (1) | NO20060443L (hr) |
| NZ (1) | NZ544181A (hr) |
| PE (1) | PE20050286A1 (hr) |
| PL (2) | PL1889621T3 (hr) |
| PT (2) | PT1889621E (hr) |
| SI (2) | SI1889621T1 (hr) |
| TW (1) | TWI357815B (hr) |
| WO (1) | WO2005000310A1 (hr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2314893C (en) | 1997-12-22 | 2005-09-13 | Euro-Celtique, S.A. | Opioid agonist/antagonist combinations |
| US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| DE60238756D1 (de) | 2001-05-11 | 2011-02-10 | Endo Pharmaceuticals Inc | Opioid enthaltende arzneiform gegen missbrauch |
| US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
| EP2957281A1 (en) | 2001-09-21 | 2015-12-23 | Egalet Ltd. | Polymer release system |
| EP1492506B2 (en) | 2002-04-05 | 2016-06-29 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
| EP2301526B1 (en) | 2003-03-26 | 2016-03-23 | Egalet Ltd. | Morphine controlled release system |
| TWI357815B (en) * | 2003-06-27 | 2012-02-11 | Euro Celtique Sa | Multiparticulates |
| TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
| GB0403098D0 (en) * | 2004-02-12 | 2004-03-17 | Euro Celtique Sa | Extrusion |
| EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
| GB2418854B (en) | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
| AU2006208627B8 (en) * | 2005-01-28 | 2009-08-13 | Mundipharma Pty Limited | Alcohol resistant dosage forms |
| EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| CA2637755A1 (en) * | 2006-01-21 | 2007-07-26 | Abbott Gmbh & Co. Kg | Dosage form and method for the delivery of drugs of abuse |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| JP5452236B2 (ja) * | 2007-03-02 | 2014-03-26 | ファーナム・カンパニーズ・インコーポレーテッド | ロウ様物質を用いた徐放性組成物 |
| CA2687979C (en) | 2007-05-25 | 2017-07-04 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of risperidone compounds |
| WO2008148798A2 (en) | 2007-06-04 | 2008-12-11 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| KR20150064227A (ko) | 2007-10-19 | 2015-06-10 | 오츠카 세이야쿠 가부시키가이샤 | 매트릭스형 의약 고형 제제 |
| JP2011511782A (ja) | 2008-02-12 | 2011-04-14 | アボット・ラボラトリーズ | 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途 |
| EP2344136B1 (en) * | 2008-09-18 | 2016-06-15 | Purdue Pharma LP | Pharmaceutical dosage forms comprising poly(e-caprolactone) |
| WO2010089132A1 (en) | 2009-02-06 | 2010-08-12 | Egalet A/S | Immediate release composition resistant to abuse by intake of alcohol |
| MX347106B (es) | 2009-03-10 | 2017-04-12 | Euro-Celtique S A * | Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona. |
| NZ597283A (en) | 2009-06-24 | 2013-07-26 | Egalet Ltd | Controlled release formulations |
| EP2534479A1 (en) * | 2010-02-11 | 2012-12-19 | Harry Leider | Methods of normalizing measured drug concentrations and testing for non-compliance with a drug treatment regimen |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| US9549899B2 (en) | 2012-07-06 | 2017-01-24 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
| CA2918004C (en) | 2013-07-23 | 2018-11-20 | Euro-Celtique S.A. | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
| CA2919892C (en) | 2013-08-12 | 2019-06-18 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| US9707184B2 (en) | 2014-07-17 | 2017-07-18 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| EP3209282A4 (en) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4861598A (en) * | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
| HUT69680A (en) * | 1990-08-09 | 1995-09-28 | Endocon Inc | Implant and apparatus for delivering multiple drug and process for production of theese |
| US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
| DE69530973T2 (de) * | 1994-02-16 | 2004-05-19 | Abbott Laboratories, Abbott Park | Verfahren zur herstellung feinteiliger pharmazeutischer formulierungen |
| US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| CN1136922C (zh) * | 1995-05-01 | 2004-02-04 | 株式会社三养社 | 可植入的可生物再吸收的膜及其制备方法 |
| SE505146C2 (sv) * | 1995-10-19 | 1997-06-30 | Biogram Ab | Partiklar för fördröjd frisättning |
| AU3404997A (en) * | 1996-05-31 | 1998-01-05 | Euro-Celtique S.A. | Sustained release oxycodone formulations with no fed/fast effect |
| US6022554A (en) * | 1997-12-15 | 2000-02-08 | American Home Products Corporation | Polymeric microporous film coated subcutaneous implant |
| IT1304152B1 (it) * | 1998-12-10 | 2001-03-08 | Mediolanum Farmaceutici Srl | Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato |
| FR2795326B1 (fr) * | 1999-06-28 | 2001-08-31 | Adir | Composition pharmaceutique solide thermoformable a liberation controlee |
| RU2230556C2 (ru) * | 1999-10-29 | 2004-06-20 | Эро-Селтик, С.А. | Препаративные формы гидрокодона с контролируемым высвобождением |
| BR0108379A (pt) * | 2000-02-08 | 2002-11-05 | Euro Celtique Sa | Composições de liberação controlada contendo agonista e antagonista opióide, método para a preparação de uma formulação em dosagem de analgésico opióide de liberação controlada com potência analgésica aumentada e sistema de administração através da derme para um analgésico opióide |
| FR2818552B1 (fr) * | 2000-12-26 | 2003-02-07 | Servier Lab | Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine |
| BR0309844A (pt) * | 2002-05-07 | 2005-02-15 | Control Delivery Sys Inc | Processos para formação de um dispositivo para a distribuição de droga |
| CN1741792A (zh) * | 2003-01-24 | 2006-03-01 | 控制递送系统有限公司 | 经眼部递送肾上腺素能剂的持续释放系统和方法 |
| TWI357815B (en) * | 2003-06-27 | 2012-02-11 | Euro Celtique Sa | Multiparticulates |
-
2004
- 2004-06-18 TW TW093117618A patent/TWI357815B/zh not_active IP Right Cessation
- 2004-06-23 DK DK07013702.1T patent/DK1889621T3/da active
- 2004-06-23 EA EA200600111A patent/EA013424B1/ru not_active IP Right Cessation
- 2004-06-23 CA CA2530385A patent/CA2530385C/en not_active Expired - Fee Related
- 2004-06-23 EP EP04743056A patent/EP1644002B1/en not_active Expired - Lifetime
- 2004-06-23 SI SI200432174T patent/SI1889621T1/sl unknown
- 2004-06-23 PL PL07013702T patent/PL1889621T3/pl unknown
- 2004-06-23 AT AT04743056T patent/ATE453394T1/de active
- 2004-06-23 ES ES07013702.1T patent/ES2490598T3/es not_active Expired - Lifetime
- 2004-06-23 BR BRPI0411901-0A patent/BRPI0411901B1/pt not_active IP Right Cessation
- 2004-06-23 ES ES04743056T patent/ES2337468T3/es not_active Expired - Lifetime
- 2004-06-23 WO PCT/GB2004/002705 patent/WO2005000310A1/en active Application Filing
- 2004-06-23 DK DK04743056.6T patent/DK1644002T3/da active
- 2004-06-23 DE DE602004024888T patent/DE602004024888D1/de not_active Expired - Lifetime
- 2004-06-23 NZ NZ544181A patent/NZ544181A/en not_active IP Right Cessation
- 2004-06-23 PT PT70137021T patent/PT1889621E/pt unknown
- 2004-06-23 JP JP2006516468A patent/JP5348841B2/ja not_active Expired - Fee Related
- 2004-06-23 KR KR1020057024940A patent/KR101116518B1/ko not_active IP Right Cessation
- 2004-06-23 AU AU2004251481A patent/AU2004251481B2/en not_active Ceased
- 2004-06-23 EP EP07013702.1A patent/EP1889621B1/en not_active Expired - Lifetime
- 2004-06-23 PL PL04743056T patent/PL1644002T3/pl unknown
- 2004-06-23 PT PT04743056T patent/PT1644002E/pt unknown
- 2004-06-23 MX MXPA05013799A patent/MXPA05013799A/es active IP Right Grant
- 2004-06-23 SI SI200431330T patent/SI1644002T1/sl unknown
- 2004-06-24 PE PE2004000617A patent/PE20050286A1/es not_active Application Discontinuation
- 2004-06-25 MY MYPI20042516A patent/MY176831A/en unknown
- 2004-06-25 AR ARP040102264A patent/AR044935A1/es not_active Application Discontinuation
-
2005
- 2005-12-21 IL IL172730A patent/IL172730A/en active IP Right Grant
-
2006
- 2006-01-27 NO NO20060443A patent/NO20060443L/no not_active IP Right Cessation
-
2010
- 2010-03-08 HR HR20100127T patent/HRP20100127T1/hr unknown
- 2010-03-19 CY CY20101100259T patent/CY1109917T1/el unknown
-
2013
- 2013-05-08 JP JP2013098685A patent/JP5960089B2/ja not_active Expired - Fee Related
-
2014
- 2014-07-04 HR HRP20140635TT patent/HRP20140635T1/hr unknown
- 2014-07-31 CY CY20141100577T patent/CY1115415T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100127T1 (hr) | Višečestični oblici | |
| ES2260253T3 (es) | Composicion farmaceutica oral de liberacion controlada y absorcion prolongada. | |
| US5133974A (en) | Extended release pharmaceutical formulations | |
| ES2625092T3 (es) | Formas de dosificación orales resistentes a la adicción y método de uso de las mismas | |
| JP2008511604A5 (hr) | ||
| ES2642788T3 (es) | Fabricación de gránulos sin principio activo y de comprimidos que comprenden los mismos | |
| HRP960554A2 (en) | Pharmaceutical formulations | |
| ES2409069A2 (es) | Uso de aglutinantes para fabricar formulaciones estables al almacenamiento | |
| PT1379222E (pt) | Comprimidos efervescentes orodispersíveis | |
| BRPI0610634A2 (pt) | combinação para a terapia de hiperplasia benigna da próstata | |
| US9387166B2 (en) | Controlled release oral dosage form comprising oxycodone | |
| CA2488868A1 (en) | Controlled release formulation of lamotrigine | |
| BR112012025015B1 (pt) | Formulações farmacêuticas para tratamento de bexiga hiperativa. | |
| JPH08208520A (ja) | 経口薬剤構成物 | |
| AU2015349896B2 (en) | Pharmaceutical bead formulations comprising dimethyl fumarate | |
| ES2680444T3 (es) | Forma de dosificación oral sólida de irinotecán para el tratamiento del cáncer | |
| ES2408343A2 (es) | Composiciones farmacéuticas que comprenden hidromorfona y naloxona | |
| CN103919715A (zh) | 含有甘磷酸胆碱或其盐的控释药物组合物及其制备方法 | |
| CA2804874C (en) | Formulations comprising coated fine particles | |
| AU2021204247A1 (en) | Pharmaceutical matrix formulations comprising dimethyl fumarate | |
| ES2321908T3 (es) | Preparaciones farmaceuticas de liberacion prolongada independientemente del ph. | |
| KR102055859B1 (ko) | 아캄프로세이트 제제, 그것의 사용 방법, 및 그것을 포함하는 조합 | |
| ES2326251B1 (es) | Composiciones de ticlopidina de liberacion modificada. | |
| JP6186139B2 (ja) | 口腔内速崩壊性錠剤 | |
| JP2018526414A5 (hr) |